Head and Neck Cancer Diagnostics Market Report 2025

The head and neck cancer diagnostics market size has grown rapidly in recent years. It will grow from $1.74 billion in 2024 to $2.05 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to tobacco and alcohol consumption, increasing aging population, awareness campaigns, biopsy techniques development, healthcare infrastructure development.

The head and neck cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $3.87 billion in 2029 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to genomic biomarkers, rising incidence of hpv-related cancers, integration of artificial intelligence (ai), immunotherapy and targeted therapies, healthcare policy and reimbursement changes. Major trends in the forecast period include liquid biopsy dominance, multi-modality diagnostics, point-of-care diagnostics, global collaborations and partnerships, digital pathology integration.

The growth in the head and neck cancer diagnostics market in the future is expected to be driven by the increasing incidence of head and neck cancer. This group of tumors affects various tissues and organs in the head and neck region, including the mouth, pharynx, larynx, salivary glands, nasal cavity, and sinuses. Head and neck cancer diagnostics play a crucial role in the early detection of the disease through tests such as incisional biopsy and barium swallow test. For example, in February 2023, the American Society of Clinical Oncology reported that head and neck cancer constituted 4% of all malignancies in the United States, with an estimated 66,920 people expected to be affected by it in 2023. This rise in incidence globally, such as in Australia, where there were 5,189 new cases in 2022, is a key driver for the growth of the head and neck cancer diagnostics market.

The increasing adoption of personalized medicines is expected to contribute to the growth of the head and neck cancer diagnostics market. Personalized medicine involves tailoring medical treatment to the individual characteristics of each patient, optimizing treatment outcomes, and minimizing side effects. Precision imaging and individualized follow-up care are crucial in managing head and neck cancers effectively. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), and approximately 34% of these, equivalent to 12 NMEs, were classified as personalized medicines by the Personalized Medicine Coalition (PMC). This adoption of personalized medicine reflects a significant trend driving the growth of the head and neck cancer diagnostics market.

Product innovation is a prominent trend gaining traction in the head and neck cancer diagnostic market, with major players focusing on developing innovative products to strengthen their market position. For example, in May 2023, Alkem Laboratories Ltd., an India-based healthcare company, introduced Cetuxa, the world's first biosimilar for treating head and neck cancer. Cetuxa is a biosimilar to cetuximab, a monoclonal antibody with anti-tumor properties that inhibits the receptor-dependent transduction pathway. It binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Clinical practice often combines cetuximab with chemotherapy or radiation therapy for treating locally advanced, recurring, or metastatic squamous cell carcinoma of the head and neck.

Major companies in the head and neck cancer diagnostics market are actively developing new products, such as antibodies, to gain a competitive advantage. Antibodies are proteins produced by the immune system in response to foreign substances. For instance, in February 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, launched IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and ATRX Rabbit Polyclonal Antibody, offering advanced features in brain cancer diagnostics. These antibodies are specifically designed to detect mutations in the IDH1 and ATRX genes, providing clinicians with crucial diagnostic and prognostic information. The IDH1 antibody identifies the IDH1 R132H mutation in adult-type gliomas and acute myeloid leukemia (AML), aiding patient stratification for clinical trials. The ATRX antibody detects mutations in the ATRX gene, offering valuable insights for clinicians managing IDH-mutant gliomas.

In May 2022, Regeneron Pharmaceuticals Inc., a US-based pharmaceutical company, acquired Checkmate Pharmaceuticals Inc. for an undisclosed amount. This acquisition is expected to enhance Regeneron Pharmaceuticals' position as a leader in immuno-oncology and expand its strategic adaptability and innovation with promising monotherapy and combination candidates for challenging malignancies. Checkmate Pharmaceuticals Inc., a US-based biopharmaceutical company, focuses on discovering and developing cancer immunotherapy approaches, including immuno-oncology treatments for head and neck cancer.

Major companies operating in the head and neck cancer diagnostics market include F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Abbott Laboratories, Siemens Healthineers AG, BioNTech AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Laboratory Corporation of America, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Shimadzu Corporation, Sysmex Corp., Varian Medical Systems Inc., QIAGEN N.V., Exact Sciences Corp., Bio-Techne Corp., Carestream Health Inc., Myriad Genetics Inc., Cepheid Inc., Invitae Corporation, Accuray Inc., Canon Medical Systems Corporation, NanoString Technologies Inc, Asuragen Inc., Caris Life Sciences Inc., HTG Molecular Diagnostics Inc., Oncgnostics GmbH, Perseus Proteomics Inc., VolitionRx Ltd.

North America was the largest region in the head and neck cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the head and neck cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Head and neck cancer diagnostics involve the identification and confirmation of malignant cells in the head and neck region through a combination of methods, including physical examination, imaging tests, medical history assessment, and tissue biopsy. This diagnostic process is commonly applied in the treatment of squamous cell carcinomas, laryngeal cancer, and hypopharyngeal cancer.

The primary methods employed in head and neck cancer diagnostics include diagnostic imaging equipment, endoscopy screening equipment, biopsy screening tests, dental diagnostic methods, and others. Diagnostic imaging equipment comprises various medical tools utilized to generate images of the internal organs and tissues for diagnostic purposes. These diagnostic processes involve multiple channels, including retail and specialty pharmacies, hospital pharmacies, and online pharmacies. The end-users benefiting from these diagnostic methods encompass hospitals, diagnostic centers, and others.

The head and neck cancer diagnostics market research report is one of a series of new reports that provides head and neck cancer diagnostics market statistics, including head and neck cancer diagnostics industry global market size, regional shares, competitors with a head and neck cancer diagnostics market share, detailed head and neck cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer diagnostics industry. This head and neck cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The head and neck cancer diagnostic market consists of revenues earned by entities by providing panoramic dental X-ray, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.